Development code · Small Molecule
SAGE-718
SAGE-718 is a development code for Dalzanemdor, developed by Sage Therapeutics, Inc..
- Status
- Discontinued for Huntington's disease
- Mechanism
- NMDA receptor PAM
- Developer
- Sage Therapeutics, Inc.
Programs
- Dalzanemdor for Huntington's diseaseDiscontinuedDiscontinued
- Dalzanemdor for Alzheimer's diseaseDiscontinuedDiscontinued
- Dalzanemdor for Parkinson's diseaseDiscontinuedDiscontinued
Also known as
- SAGE718
- dalzanemdor
- 1629853-48-0
- (3S,8S,9S,10R,13R,14S,17R)-3,10,13-trimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol